|
|
Article: Merck Pays More Than $400 Million to Settle Federal, State Medicaid Fraud Investigation Sparked by Qui Tam Whistleblower Case Detailing Marketing Schemes for Vioxx(R), Zocor(R), Several Other Drugs.
- Article from:
- PR Newswire
- Article date:
- February 7, 2008
|
Copyright informationCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
PHILADELPHIA, Feb. 7 /PRNewswire/ -- One of the world's largest drug manufacturers, Merck & Co., Inc. ("Merck"), has agreed to pay more than $400 million to the U.S., 49 states and the District of Columbia to settle qui tam whistleblower-led allegations that the pharmaceutical giant illegally defrauded Medicaid and other public healthcare programs across the U.S., according to a federal Settlement Agreement unsealed today. Merck employed four schemes to grab or maintain market share for drugs including Vioxx(R), Zocor(R), Cozaar(R), Fosamax(R), Maxalt(R), and Singulair(R), according to qui tam whistleblower lawyers Steven H. Cohen, Mark Kleiman and BethAnne Yeager, who ...
Related newspaper, magazine, and journal articles:
|
|
Article: SEN. LITTLE, SENATE COLLEAGUES ANNOUNCE PLAN TO FIGHT MEDICAID FRAUD
US Fed News Service, Including US State News;
March 7, 2006 ;
539 words
......announced an aggressive plan to combat Medicaid fraud that they are estimating would save...Senate Medicaid Reform Task Force. The Medicaid Fraud Prevention and Recovery Reform Act...desperately needed changes this year." The Medicaid Fraud Prevention and Recovery Reform Act...
|
|